Active Recombinant Human IFNB1 Protein

• Cat.No.: IFNB1-082H
• Product Overview: The mature recombinant human IFN- β protein (22-187aa) without tag was expressed in E. coli.

Specification

• Description: This gene encodes a cytokine that belongs to the interferon family of signaling proteins, which are released as part of the innate immune response to pathogens. The protein encoded by this gene belongs to the type I class of interferons, which are important for defense against viral infections. In addition, type I interferons are involved in cell differentiation and anti-tumor defenses. Following secretion in response to a pathogen, type I interferons bind a homologous receptor complex and induce transcription of genes such as those encoding inflammatory cytokines and chemokines. Overactivation of type I interferon secretion is linked to autoimmune diseases. Mice deficient for this gene display several phenotypes including defects in B cell maturation and increased susceptibility to viral infection.
• Source: E. coli
• Species: Human
• Bio-activity: Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 5-30 pg/mL.
  The specific activity of Recombinant Human IFN-beta is approximately 2.8 x 108 IU/mg, which is calibrated against human IFN- beta WHO International Standard (NIBSC code: 00/572).
• Molecular Mass: 20 kDa
• Product-Related Proteins: 22-187
• Endotoxin: < 0.1 EU/μg of the protein as determined by the LAL method
• Purity: > 95 % as determined by SDS-PAGE
• Storage: At -80 centigrade. Avoid repeated freeze-thaw cycles.
• Storage Buffer: PBS
• Protein length: 22-187

Gene Information

• Gene Name: IFNB1 interferon beta 1 [ Homo sapiens (human) ]
• Official Symbol: IFNB1
• Synonyms: IFNB1; interferon beta 1; IFB; IFF; IFNB; IFN-beta; interferon beta; fibroblast interferon; interferon, beta 1, fibroblast; interferon-beta
• Gene ID: 3456
• mRNA Refseq: NM_002176
• Protein Refseq: NP_002167
• MIM: 147640
• UniProt ID: P01574

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.